Dovetail Technologies

Dovetail Technologies was a Maryland-based biotechnology company specializing in the development of bifunctional small molecules known as Dovetail compounds. These molecules were designed to treat cancer and infectious diseases by bridging target cells or pathogens with the body's natural immune system components, such as pre-existing antibodies. The company's platform technology aimed to provide a versatile approach to immunotherapy without the need for complex biologics. In 2001, the company was acquired by Progenics Pharmaceuticals, which sought to integrate Dovetail's platform into its own portfolio of therapeutic and diagnostic products.